Clinton and Trump are keeping mum about some healthcare issues, and that’s raising some critical questions. Managed Healthcare Executive asked industry experts to comment on what topics presidential candidates are being quiet about, and why they suspect they’re not talking about them.
A new survey from Willis Towers Watson has interesting findings related to how employers view exchange viability
Shifting patient demographics will create an ideal scenario for the online/mail-order pharmacy market in the next five to ten years.
The impacts of the ever-changing health care marketplace and how employers, brokers and carriers have adapted
Over the next decade, health spending is expected to grow at an average rate of 5.8% per year.
FDA approved evolocumab (Repatha, Amgen) Pushtronex system, the first monthly single-dose injection of a PCSK9 inhibitor. Repatha was already approved by FDA as the only PCSK9 inhibitor with a monthly dose last August.
A new study suggests that patients are willing to use antibiotics without contacting a doctor. Here’s how execs can curb this and avoid antibiotic resistance.
Find out what drives patients to international destinations for treatments and what these destinations provide.
As payers look for growth opportunities internationally, they should watch nother growing trend: medical tourism.
Despite different drivers among healthcare leaders, telehealth is gaining momentum. Still, key barriers need to be addressed.
Expanding access to buprenorphine, a medication to treat opioid use disorder, is one of several new actions announced by Health and Human Services (HHS) to combat the opioid epidemic. Here are the top 4 new provisions from HHS.
From new outreach programs to multidisciplinary teams, here are some new strategies health plans are employing to fight the opioid epidemic
HHS is taking formal steps to address opioid addiction, a widely recognized national public health crisis. Find out the policy changes.
A new KFF issue brief finds that healthcare coverage problematic for some, even as coverage is gained through the ACA.
For the first time, FDA approved dronabinol oral solution (Syndros, Insys Therapeutics), a liquid formulation of the pharmaceutical cannabinoid dronabinol, a pharmaceutical version of tetrahydrocannabinol ("THC").
Karen B. DeSalvo, National Coordinator for Health Information Technology, gives the best courses of action for top technology challenges and opportunities facing healthcare executives.
A new Quest Diagnostics and Inovalon study cites barriers to value-based care, but offers advice on how to overcome them.
As asthma prevalence continues to rise in the adult and pediatric populations, U.S. healthcare spending on medications, especially branded inhalers, is expected to increase.
Express Scripts Exchange Pulse report found that utilization, particularly for traditional meds, was one of the biggest factors driving spending in 2015, accounting for more than half of the exchange plans $99 PMPY increase in spending between 2014 and 2015.
CMS finalized new rules that aim to enrich the Qualified Entity Program by expanding access to analyses and data that will help providers, employers, and others make more informed decisions about care delivery and quality improvement.
All antibiotic use has the potential to contribute to the development of antibiotic resistance. That’s why it is key to reduce inappropriate antibiotic use in order to slow the growth of resistance.
Health plans must find new and meaningful ways to connect with patients of diverse backgrounds.
Remote monitoring studies are missing the mark when assessing the value of the technology. Here’s why.
Is digital health integration the missing link in understanding chronic diseases and what should physicians be asking to ensure the data they want to receive is captured effectively?
Payers pair with providers to manage patients with chronic disease at a distance.
Many health systems have a hard time capturing and using data from patients that can make a real impact on their businesses. Here are some innovative projects to have on your radar.
Cyberattacks based on ransomware-hacking into a computer system and holding it hostage until the victim pays to regain access-are on the rise.
Multiple factors are moving mental healthcare to a front burner issue in managed care.
In an era when adherence to specialty pharmaceuticals is disturbingly low, value-based pricing needs real-world results, not single-arm accelerated trials.
A new drug approved by FDA to treat chronic hepatitis C virus (HCV) infection this week enters a competitive, lucrative market headed up by Gilead Science’s Sovaldi and Harvoni, as well as AbbVie’s Viekira Pak. FDA granted priority review and breakthrough therapy designation to Gilead’s combination product, Epclusa (sofosbuvir 400 mg/velpatasvir 100 mg).